论文部分内容阅读
目的了解VAD方案治疗多发性骨髓瘤的疗效。方法长春新碱1mg/m2d1,盐酸阿霉素40mg/m2d1,醋酸地塞米松片40mg/d口服第1～4、9～12、17～20、28天为一疗程,连用2周后评价疗。一直到骨髓瘤的M蛋白获最大程度的减少后再用4个周期。阿霉素的累积量不得超过540mg/m2。为避免肾上腺皮质激素过量问题,酯酸地塞米松所给的频度应在临床缓解达到后逐渐减量。结果10例中,CR4例,占40%,PR4例,占40%,SD2例,占20%,PD0例。总有效率(CR+PR)为80%。不良反应主要为恶心、呕吐、骨髓抑制、脱发等。结论VAD方案治疗多发性骨髓瘤疗效高、安全性好、副反应少。
Objective To understand the efficacy of VAD regimen in the treatment of multiple myeloma. Methods vincristine 1mg / m2d1, doxorubicin hydrochloride 40mg / m2d1, dexamethasone acetate tablets 40mg / d oral 1 ~ 4,9 ~ 12,17 ~ 20,28 days for a course of treatment, once 2 weeks after evaluation of treatment . Up to 4 cycles until myeloma M protein is maximally reduced. Adriamycin accumulation of not more than 540mg / m2. In order to avoid excessive corticosteroid problems, the frequency of dexamethasone given should be gradually reduced after clinical remission has been achieved. Results Among 10 cases, CR4 cases accounted for 40%, PR4 cases accounted for 40%, SD2 cases, 20%, PD0 cases. The total effective rate (CR + PR) was 80%. Adverse reactions mainly nausea, vomiting, bone marrow suppression, hair loss and so on. Conclusions VAD regimen is effective in treating multiple myeloma with good safety and few side effects.